Avenanthramide A
Based on 1 Customer Validation
Avenanthramide A is an orally active phytoalexin that targets the RNA helicase DDX3 with a KD of 8.8 μM. Avenanthramide A induces mitochondrial swelling and increased ROS production, and triggers apoptosis in CRC cells. Avenanthramide A inhibits smooth muscle cell proliferation and enhances nitric oxide production. Avenanthramide A can be used in research on colorectal cancer and atherosclerosis.
For research use only. We do not sell to patients.
- Purity: 98.35%
- CAS No.: 108605-70-5
- Formula: C16H13NO5
- Molecular Weight:299.28
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
NF-κB Signaling Compound Library
HY-L014
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Phenols Library
HY-L057
-
Orally Active Compound Library
HY-L061
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Anti-Cancer Natural Product Library
HY-L107
-
Plant-Sourced Natural Product Library
HY-L115
-
Human Metabolite Library
HY-L123
-
Cysteine Targeted Covalent Library
HY-L153
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Natural Product Diversity Scaffold Library
HY-L245
-
Lactylation Compound Library
HY-L249
-
Mass Spectrometry Natural Product Library
HY-L262
All DNA/RNA Synthesis Isoforms
More
Biological Activity
|
Helicase |
Avenanthramide A binds most tightly to the ATP-binding domain-containing truncated DDX31-306 mutant (Kd = 7.11 μM), with weaker binding to the N-terminal DDX31-215 (Kd = 13.85 μM) and C-terminal DDX3307-662 (Kd = 36.25 μM) mutants[1].
Avenanthramide A (30 μM) potently inhibits the ATPase activity of purified recombinant human DDX3 protein[1].
Avenanthramide A selectively reduces the viability of human DLD1 colorectal cancer cells while having minimal effect on normal human FHC colonic epithelial cells[1].
Avenanthramide A (30 μM; 24 h) has reduced ability to suppress viability of human DLD1 colorectal cancer cells expressing DDX3R287A or DDX3R294A mutants, indicating these residues are critical for its anti-tumor activity[1].
Avenanthramide A (30 μM) downregulates NDUFS2 and UQCRC1 expression in human DLD1 colorectal cancer cells expressing wild-type DDX3, DDX3K255A, or DDX3S290A, but not in cells expressing DDX3R287A or DDX3R294A[1].
Avenanthramide A (30 μM) induces ROS production in human DLD1 colorectal cancer cells expressing wild-type DDX3, DDX3K255A, or DDX3S290A, but not in cells expressing DDX3R287A or DDX3R294A[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human colorectal cancer DLD1 cells expressing wild-type or mutant DDX3 (K255A, R287A, S290A, R294A)
-
Concentration:30 μM
-
Incubation Time:24 h
-
Result:Reduced viability of cells expressing wild-type DDX3, DDX3-K255A, or DDX3-S290A.
Showed reduced ability to suppress viability of cells expressing DDX3-R287A or DDX3-R294A mutants, with significantly higher viability compared to wild-type or other mutant groups.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice[1]
-
Dosage:30 mg/kg
-
Administration:p.o.; daily; 21 days
-
Result:Reduced tumor weights significantly compared to vehicle control.
Suppressed tumor volume growth, maintaining tumor volume near 100 mm3 over 21 days while control tumors grew to ~450 mm3.
Decreased GSH/GSSG ratio in tumor tissue significantly with no change in blood.
Reduced Ki67 and DDX3 expression significantly in tumor tissues.
Increased cleaved-caspase-3 expression in tumor tissues.
Caused no histopathological signs of liver or kidney injury.
Induced no significant changes in body weight during treatment.
Chemical Information
-
CAS No. 108605-70-5
-
Appearance Solid
-
Molecular Weight 299.28
-
Formula C16H13NO5
-
Color White to light brown
-
SMILES
O=C(C1=CC(O)=CC=C1NC(/C=C/C2=CC=C(C=C2)O)=O)O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 100 mg/mL (334.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.35 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.35 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (285 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
[1]. Fu R, et al. Avenanthramide A triggers potent ROS-mediated anti-tumor effects in colorectal cancer by directly targeting DDX3. Cell Death Dis. 2019;10(8):593. Published 2019 Aug 7. [Content Brief]
[2]. Nie L, et al. Avenanthramide, a polyphenol from oats, inhibits vascular smooth muscle cell proliferation and enhances nitric oxide production. Atherosclerosis. 2006;186(2):260-266. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3414 mL | 16.7068 mL | 33.4135 mL | 83.5338 mL |
| 5 mM | 0.6683 mL | 3.3414 mL | 6.6827 mL | 16.7068 mL | |
| 10 mM | 0.3341 mL | 1.6707 mL | 3.3414 mL | 8.3534 mL | |
| 15 mM | 0.2228 mL | 1.1138 mL | 2.2276 mL | 5.5689 mL | |
| 20 mM | 0.1671 mL | 0.8353 mL | 1.6707 mL | 4.1767 mL | |
| 25 mM | 0.1337 mL | 0.6683 mL | 1.3365 mL | 3.3414 mL | |
| 30 mM | 0.1114 mL | 0.5569 mL | 1.1138 mL | 2.7845 mL | |
| 40 mM | 0.0835 mL | 0.4177 mL | 0.8353 mL | 2.0883 mL | |
| 50 mM | 0.0668 mL | 0.3341 mL | 0.6683 mL | 1.6707 mL | |
| 60 mM | 0.0557 mL | 0.2784 mL | 0.5569 mL | 1.3922 mL | |
| 80 mM | 0.0418 mL | 0.2088 mL | 0.4177 mL | 1.0442 mL | |
| 100 mM | 0.0334 mL | 0.1671 mL | 0.3341 mL | 0.8353 mL |
Avenanthramide A Related Classifications
HY-114977 Related Classifications
Powered by Bioz